NCT05760196招募中2 期
A Prospective, Multicenter, High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors and GM-CSF in the Treatment of Advanced Recurrent Metastatic Head and Neck Tumors
Xiangpan Li1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2022年10月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is an intervention study, aiming to use high and low dose radiotherapy combined with PD-1/PD-L1 inhibitor combined with GM-CSF to observe the effect of anti-tumor immunity and long-term therapeutic response rate, and to explore a new treatment model for patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old;
- •Patients with recurrent or metastatic advanced head and neck malignancies (including nasopharyngeal malignancies), with a clear pathological diagnosis, imaging diagnosis, and medical history, no clearly recommended standard treatment regimen or inability to tolerate standard treatment regimens, and clear measurable lesions (>1 cm);
- •Patients with squamous cell carcinoma who progress after first-line antineoplastic therapy must include a platinum-containing combination chemotherapy or platinum-based concurrent chemoradiotherapy, and patients with secondary resistance after previous anti-PD-1/L1 therapy may also be enrolled;
- •There is no standard regimen recommended by guidelines after first-line treatment failure in patients with non-squamous cell carcinoma (eg, adenoid cystadenocarcinoma, lung metastases, sarcoma, etc.);
- •At least one lesion with a diameter of 1 cm to 5 cm (metastases ≥1 cm, if the patient has large metastases, partial tumor irradiation can be allowed) can be treated with radiation therapy at 16 to 24 Gy/2-3Fx doses; Lymph nodes can be used as stand-alone measurable lesions (if lymph nodes are evaluated as an evaluation lesion, they must meet the criteria for target lesions, see RECIST1.1 for definition of a lymph node target lesion);
- •Patients who have previously received radical radiotherapy need to have an interval of more than 6 months; Patients with an interval of more than 6 months from the previous radiotherapy;
- •In the past 6 months, there has been no acute coronary syndrome or malignant arrhythmia;
- •ECOG (Eastern Cooperative Oncology Group), score 0-2, life expectancy assessment ≥ 3 months;
- •There were no previous severe hematopoietic, cardiac, pulmonary, hepatic, or renal dysfunction or immunodeficiency;
- •Ejection fraction of cardiac color Doppler ultrasound ≥ 50%;
- •Myocardial enzyme profile and NT-proBNP do not exceed twice the upper limit of normal;
- •Troponin and CKMB values do not exceed twice the normal upper limit;
- •Patients who have had grade 2 or higher AV block in the past six months and need to consider pacemakers will not be included;
- •Blood pressure hypertension≤ 160mmHg and/or low pressure≤90mmHg. 1 week prior to enrollment, the level of organ function meets the following criteria:
- •Bone marrow function: hemoglobin ≥ 80g/L, white blood cell count ≥ 3.5*10^9/L or neutrophil count ≥1.5*10^9/L, platelet count ≥ 100*10^9/L, CD8+ T lymphocyte absolute value ≥200/μL; Liver: serum total bilirubin level ≤ 1.5 times the upper limit of normal, when the serum total bilirubin level > 1.5 times the upper limit of normal, direct bilirubin level must ≤ the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal; (5.0 times ≤the upper limit of normal in patients with liver metastases); Kidney: serum creatinine level < 1.5 times the upper limit of normal or creatinine clearance ≥ 50ml/min, urea nitrogen ≤ 200mg/L; serum albumin≥ 30g/L;
- •Patients must have the ability to understand and voluntarily sign informed consent forms.
排除标准
- •Exclude single shot oligo transfer;
- •Pregnant or breastfeeding women;
- •Those who have a history of other malignant diseases in the past 5 years, except for cured skin cancer and cervical carcinoma in situ;
- •Patients with a history of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders, as judged by the investigator, may hinder the signing of informed consent or affect the patient's adherence to drug therapy;
- •Clinically severe (i.e., active) heart disease such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more congestive heart failure or severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months;
- •Organ transplantation requires immunosuppressive therapy;
- •Known major active infection, or major blood, kidney, metabolic, gastrointestinal, endocrine function or metabolic disorders, or other serious uncontrolled concomitant diseases. Those who are allergic to any of the ingredients used in the study;
- •Those with a history of immunodeficiency, including those who test positive for HIV or have other acquired or congenital immunodeficiency disorders, or have a history of organ transplantation, or who have other immune-related disorders that require long-term oral hormone therapy;
- •Are in the period of acute and chronic TB infection (positive T-spot test, chest x-ray in patients with suspected tuberculosis);
- •Other circumstances that the investigator does not consider suitable for inclusion.
研究组 & 干预措施
Recurrent or metastatic advanced head and neck malignancy
Experimental
Patients with a clear pathological diagnosis, imaging diagnosis, and history, no clear recommended standard treatment or inability to tolerate standard treatment, and a clear measurable lesion
干预措施: GM-CSF (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 36 months
Objective tumor response, including CR and PR, was assessed using RECIST version 1.1.
次要结局
- Toxic reaction(36 months)
- Overall survival(36 months)
- Duration of remission(36 months)
- Disease control rate(36 months)
- Progression-free survival(36 months)
研究者
Xiangpan Li
Professor
Renmin Hospital of Wuhan University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLMColorectal Liver MetastasesNCT06045286Jiangsu Cancer Institute & Hospital30
招募中
2 期
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal CarcinomaRadiotherapyPD-1 InhibitorCapecitabineNasopharyngeal CarcinomaNCT05290194Fifth Affiliated Hospital, Sun Yat-Sen University28
招募中
2 期
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLEarly-stageExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-TypeNCT05149170Chinese Academy of Medical Sciences30
招募中
2 期
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerAdenocarcinomaStomach NeoplasmGastroesophageal-junction CancerOligometastatic DiseaseMetastatic CancerMetastatic Gastric CancerAdenocarcinoma of the StomachGastroesophageal Junction AdenocarcinomaMetastatic AdenocarcinomaNCT06121700Fudan University55
招募中
不适用
High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid TumorMetastatic CancerNCT05755009Jiangxi Provincial Cancer Hospital33